Tags : Related Assets

Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to

Tuba Khan June 13, 2019

Shots: Novimmune to receive $115.86M, out of $518.76M and has already received $402.9M under its exclusive license agreement signed with Sobi in 2018. Sobi to get IP & patent rights, […]readmore

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company